Glaukos Corp. (GKOS), a pharmaceutical and medical technology company focused on ophthalmic therapies, secured FDA approval on October 20 for Epioxa, its non-invasive topical therapy for keratoconus. The announcement follows steady Q2 revenue growth and precedes a key regulatory decision for iDose TR, expected by December 20. With multiple programs in development and a new manufacturing site underway, Glaukos continues to execute across clinical, regulatory, and operational fronts.
FDA Approves Epioxa for Keratoconus
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.